Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery

融资将加速开发与人类相关的生物数据基础设施、虚拟细胞技术以及下一代药物发现。

BOSTON

波士顿

,

，

June 29, 2026

2026年6月29日

/PRNewswire/ -- Xellar Biosystems today announced the closing of $50 million in Series A and A+ financing to advance its vision of building the world's leading 3D Bio Intelligence platform. The financing will support the expansion of Xellar's integrated technology stack spanning organ-on-chip systems, laboratory automation, high-content imaging, multi-omics analysis, and AI-driven biological modeling..

/美通社/ -- Xellar Biosystems 今日宣布完成5,000万美元的A轮及A+轮融资，以推进其打造全球领先的3D生物智能平台的愿景。该笔资金将支持Xellar扩展其集成技术栈，涵盖器官芯片系统、实验室自动化、高内涵成像、多组学分析以及人工智能驱动的生物建模。

Drug discovery remains one of the most challenging and resource-intensive endeavors in modern science. Despite remarkable advances in artificial intelligence, the industry continues to face a fundamental bottleneck: the lack of scalable, human-relevant biological data. Xellar was founded on the belief that the future of drug discovery will be built upon a new generation of biological infrastructure capable of generating, understanding, and ultimately predicting human biology..

药物研发仍然是现代科学中最具挑战性且资源最密集的领域之一。尽管人工智能取得了显著进展，该行业仍面临一个根本性瓶颈：缺乏可扩展且与人体相关的生物数据。Xellar 的创立基于这样一种信念：药物研发的未来将建立在新一代生物基础设施之上，这种基础设施能够生成、理解并最终预测人类生物学特征。

At the core of Xellar's platform is a closed-loop system that combines human organ-on-chip models, automated experimentation, and computational intelligence. By continuously generating high-quality, multi-dimensional biological data under physiologically relevant conditions, Xellar is creating the foundation for a new class of biological foundation models and virtual cell systems..

Xellar平台的核心是一个闭环系统，融合了人体器官芯片模型、自动化实验和计算智能。通过在生理相关条件下持续生成高质量、多维度的生物数据，Xellar正在为新一代生物基础模型和虚拟细胞系统奠定基础。

Unlike traditional preclinical approaches that rely heavily on animal models or simplified in vitro assays, Xellar captures biological processes in dynamic, high-dimensional space, enabling deeper insights into mechanism of action, toxicity, disease progression, and therapeutic response. This combination of human-relevant biology and machine intelligence allows researchers to move beyond observation toward prediction..

与严重依赖动物模型或简化体外检测的传统临床前方法不同，Xellar 在动态高维空间中捕捉生物过程，从而更深入地洞察作用机制、毒性、疾病进展和治疗反应。这种将具有人类相关性的生物学与机器智能相结合的方法，使研究人员能够超越观察，迈向预测。

'AI alone will not revolutionize drug discovery,' said Xin Xie, PhD, Founder and CEO of Xellar. 'The future belongs to organizations that can generate high-quality human data at scale. We believe organ-on-chip systems, automation, and AI must work together in a closed-loop flywheel. Our mission is to transform biology from something we observe into something we can systematically understand, model, and ultimately predict.'.

“仅靠人工智能无法彻底变革药物发现，”Xellar 创始人兼首席执行官谢欣博士表示。“未来属于那些能够大规模生成高质量人类数据的机构。我们认为，类器官芯片系统、自动化和人工智能必须在闭环飞轮中协同运作。我们的使命是将生物学从一门观察性科学转变为一门我们可以系统性地理解、建模并最终预测的科学。”

With this financing, Xellar will further expand its automated biological data generation capabilities, strengthen its AI and computational biology teams, and accelerate the development of virtual cell technologies that bridge experimental biology and computational modeling.

通过此次融资，Xellar 将进一步扩大其自动化生物数据生成能力，加强人工智能和计算生物学团队，并加速开发连接实验生物学与计算建模的虚拟细胞技术。

By combining human-relevant biological systems with machine intelligence, Xellar aims to redefine how medicines are discovered and developed, enabling a future where biological innovation becomes faster, more predictive, and fundamentally more scalable.

Xellar 旨在通过将具有人类相关性的生物系统与机器智能相结合，重新定义药物的发现与开发方式，从而推动生物创新迈向更快、更具预测性且从根本上更易扩展的未来。

About Xellar

关于 Xellar

Xellar Biosystems is an AI-driven biotech company using Organ-on-a-Chip (OoC) technology, advanced imaging, and machine learning to accelerate drug discovery and development by creating realistic 3D human tissue models for testing drugs, assessing toxicity, and predicting clinical outcomes more efficiently than traditional methods.

Xellar Biosystems 是一家由人工智能驱动的生物科技公司，利用器官芯片（OoC）技术、先进成像和机器学习，通过创建逼真的3D人体组织模型来加速药物发现与开发。这些模型用于药物测试、毒性评估以及临床结果预测，相比传统方法更为高效。

Founded in 2022, they combine wet-lab experiments with AI to analyze complex biological data, aiming to reduce costs, time, and improve the success rate of bringing new therapies to market, serving the biopharmaceutical industry..

该公司成立于2022年，将湿实验室实验与人工智能相结合，用于分析复杂的生物数据，旨在降低成本、缩短时间并提高新疗法上市的成功率，服务于生物医药行业。

SOURCE Xellar Biosystems

来源：Xellar Biosystems

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示